MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacep.2017.07.005

Медицинская библиотека · JACC. Clinical electrophysiology · 2017

Hemodynamic Support in Ventricular Tachycardia Ablation: An International VT Ablation Center Collaborative Group Study.

Turagam Mohit K, Vuddanda Venkat, Atkins Donita, Santangeli Pasquale, Frankel David S, Tung Roderick, Vaseghi Marmar, Sauer William H, Tzou Wendy, Mathuria Nilesh, Nakahara Shiro, Dickfeld Timm M, Bunch T Jared, Weiss Peter, Di Biase Luigi, Tholakanahalli Venkat, Vakil Kairav, Tedrow Usha B, Stevenson William G, Della Bella Paolo, Shivkumar Kalyanam, Marchlinski Francis E, Callans David J, Natale Andrea, Reddy Madhu, Lakkireddy Dhanunjaya

Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study sought to evaluate the clinical outcomes of patients receiving hemodynamic support (HS) during ventricular tacchycardia (VT) ablation.

BACKGROUND

There are limited real-world data evaluating its effect of HS in ablation outcomes.

METHODS

An analysis of 1,655 patients from the International VT Ablation Center Collaborative group was performed. A total of 105 patients received HS with percutaneous ventricular assist device.

RESULTS

Patients in the HS group had lower left ventricular ejection fraction (LVEF), higher New York Heart Association (NYHA) functional class, and more implantable cardioverter-defibrillator (ICD) shocks, VT storm, and antiarrhythmic drug use (all p < 0.05). The HS group also required significantly longer fluoroscopy, procedure, and total lesion time. Acute procedural success (71.8% vs. 73.7%; p = 0.04) was significantly lower and complications (12.5% vs. 6.5%; p = 0.03) and 1-year mortality (34.7% vs. 9.3%; p < 0.001) were significantly higher in the HS group. Multivariate Cox regression analysis demonstrated HS as an independent predictor of mortality (hazard ratio: 5.01; 95% confidence interval: 3.44 to 7.20; p < 0.001). There was no significant difference in VT recurrence between groups. In a subgroup analysis including LVEF ≤20% and NYHA functional class III to IV patients, acute procedural success (74.0% vs. 70.5%; p = 0.8), complications (15.6% vs. 7.8%; p = 0.2), VT recurrence (30.2% vs. 38.1%; p = 0.44), and 1-year mortality (40.0% vs. 28.8%; p = 0.2) were no different between the HS and no-HS groups.

CONCLUSIONS

Patients requiring HS were sicker with multiple comorbidities and, as expected, had a significantly higher 1-year mortality than did those patients in the no-HS group. In patients with LVEF ≤20% and NYHA functional class III to IV, there was also no significant difference in clinical outcomes when compared with no HS. Further studies are needed to systematically evaluate patients undergoing VT ablation receiving HS.

Для цитирования: Turagam Mohit K, Vuddanda Venkat, Atkins Donita, Santangeli Pasquale, Frankel David S, Tung Roderick, Vaseghi Marmar, Sauer William H, Tzou Wendy, Mathuria Nilesh, Nakahara Shiro, Dickfeld Timm M, Bunch T Jared, Weiss Peter, Di Biase Luigi, Tholakanahalli Venkat, Vakil Kairav, Tedrow Usha B, Stevenson William G, Della Bella Paolo, Shivkumar Kalyanam, Marchlinski Francis E, Callans David J, Natale Andrea, Reddy Madhu, Lakkireddy Dhanunjaya. Hemodynamic Support in Ventricular Tachycardia Ablation: An International VT Ablation Center Collaborative Group Study.. JACC. Clinical electrophysiology. 2017. DOI: 10.1016/j.jacep.2017.07.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.